Clinical Data Novo says oral semaglutide works in diabetic kids PharmaphorumNovo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.Clinical DataMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaphorum Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO changeNext: BBOT shakes up leadership as RAS competitors get more visibility Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
